Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials: Experience in a Phase 1b Clinical Trial

Alzheimer Disease and Associated Disorders
Jeff SevignyJerome Barakos

Abstract

Amyloid positron emission tomography (PET) imaging is being investigated as a screening tool to identify amyloid-positive patients as an enrichment strategy for Alzheimer disease (AD) clinical trial enrollment. In a multicenter, phase 1b trial, patients meeting clinical criteria for prodromal or mild AD underwent florbetapir PET scanning at screening. PET, magnetic resonance imaging, and coregistered PET/magnetic resonance imaging scans were reviewed by 2 independent readers and binary visual readings tabulated. Semiquantitative values of cortical to whole cerebellar standard uptake value ratios were computed (threshold 1.10). Of 278 patients with an evaluable PET scan, 170 (61%) and 185 (67%) were amyloid-positive by visual reading and quantitative analysis, respectively; 39% were excluded from the study due to an amyloid-negative scan based on visual readings. More ApoE ε4 carriers than noncarriers were amyloid-positive (80% vs. 43%). Comparison of visual readings with quantitative results identified 21 discordant cases (92% agreement). Interreader and intrareader agreements from visual readings were 98% and 100%, respectively. Amyloid PET imaging is an effective and feasible screening tool for enrollment of amyloid-positive ...Continue Reading

References

May 22, 2009·NeuroImage·Aniket JoshiJeffrey A Fessler
Oct 20, 2009·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Seok Rye ChoiHank F Kung
Oct 12, 2010·Lancet Neurology·Bruno DuboisPhilip Scheltens
Jan 20, 2011·JAMA : the Journal of the American Medical Association·Christopher M ClarkUNKNOWN AV45-A07 Study Group
Aug 31, 2012·The New England Journal of Medicine·Lucie YangCharles Ganley
Oct 31, 2012·Annals of Neurology·Susan M LandauUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Nov 21, 2012·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Rik OssenkoppeleBart N M van Berckel
Nov 21, 2012·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Susan M LandauUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Jan 31, 2013·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Keith A JohnsonUNKNOWN Amyloid Imaging Taskforce
Mar 13, 2013·Lancet Neurology·Victor L VillemagneUNKNOWN Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group
Apr 5, 2013·Frontiers in Aging Neuroscience·Shannon L RisacherUNKNOWN Alzheimer's Disease Neuroimaging Initiative (ADNI)†
Jan 24, 2014·The New England Journal of Medicine·Rachelle S DoodyUNKNOWN Solanezumab Study Group
Jan 24, 2014·The New England Journal of Medicine·Stephen SallowayUNKNOWN Bapineuzumab 301 and 302 Clinical Trial Investigators
Mar 31, 2015·JAMA Neurology·Jon B ToledoUNKNOWN Alzheimer’s Disease Neuroimaging Initiative Investigators
Apr 22, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Lieke L SmitsWiesje M van der Flier

❮ Previous
Next ❯

Citations

Sep 2, 2016·Nature·Jeff SevignyAlfred Sandrock
Nov 12, 2016·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Keith N FargoZaven Khachaturian
Aug 3, 2017·Clinical and Translational Science·Jeffrey Cummings
May 4, 2018·Movement Disorders : Official Journal of the Movement Disorder Society·Jesse M Cedarbaum
Nov 14, 2018·Radiographics : a Review Publication of the Radiological Society of North America, Inc·Tamara F LundeenPhillip H Kuo
Nov 6, 2018·Annals of Neurology·Audrey GabelleUNKNOWN Multi-Domain Intervention Alzheimer's Prevention Trial study groups
Nov 8, 2018·Journal of Parkinson's Disease·Kalpana M MerchantUNKNOWN and The Michael J. Fox Foundation Alpha Synuclein Clinical Path Working Group
May 7, 2019·Glia·Ksenia V KastanenkaElena Galea
Jun 25, 2019·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Daniela PeraniUNKNOWN IMBI Project
Jun 14, 2019·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Clive BallardLars Lau Raket
Jun 25, 2018·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Jeffrey Cummings
Jul 10, 2019·Dementia & Neuropsychologia·Lucas N C PelegriniFrancisco A C Vale
Sep 1, 2018·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Jeffrey L Cummings, Nadia Fulkerson
Feb 11, 2020·Current Opinion in Psychiatry·Júlia C LoureiroLeonardo Cruz de Souza
Sep 1, 2019·Alzheimer's Research & Therapy·Jeffrey CummingsPhilip Scheltens
Mar 21, 2017·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Jason KarlawishMaria C Carrillo
Jan 4, 2018·Annals of Clinical and Translational Neurology·Jia-Jie MoJin-Shan Feng
Nov 10, 2018·Journal of Alzheimer's Disease : JAD·Sarah J BanksUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
May 19, 2019·Journal of Neurology·David C PerryBruce L Miller
Jun 19, 2019·Annals of Clinical and Translational Neurology·Leonardo IaccarinoUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Mar 12, 2019·Scientific Reports·Benjamin GoudeyUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Apr 19, 2017·Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging·Shil PatelJack Hoppin
Aug 17, 2016·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Jeffrey CummingsGaram Lee
Jul 28, 2020·Journal of Alzheimer's Disease : JAD·Gemma LombardiSandro Sorbi
Jul 23, 2020·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Jeffrey CummingsKate Zhong
Oct 29, 2020·The Journal of Neuropsychiatry and Clinical Neurosciences·Jeffrey Cummings
Jan 15, 2021·Molecular Neurodegeneration·Jeffrey Cummings
Mar 23, 2021·Clinical and Translational Imaging : Reviews in Nuclear Medicine and Molecular Imaging·Jay S WrightPeter J H Scott
Aug 14, 2020·ACS Chemical Neuroscience·Raeann M DaltonJacob M Hooker
Feb 12, 2017·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Santiago BullichSusan De Santi
Jun 5, 2021·Nature Medicine·Oskar Hansson
Apr 23, 2021·Clinical Nuclear Medicine·Katherine ZukotynskiVincent Gaudet
Jul 10, 2021·Nature Reviews. Neurology·Harald HampelAndrea Vergallo
Jun 9, 2020·Dementia and Geriatric Cognitive Disorders·Jeffrey L Cummings

❮ Previous
Next ❯

Methods Mentioned

BETA
genotyping

Clinical Trials Mentioned

NCT01677572

Software Mentioned

Freesurfer

Related Concepts

Related Feeds

Alzheimer's Disease: APOE

Apolipoprotein E (APOE) polymorphic alleles are major genetic risk factors for Alzheimer's disease. Discover the latest research on APOE and other genetic determinants of Alzheimer's disease here.

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.